Serum 25-hydroxyvitamin D levels in early and advanced breast cancer. Issue 12 (17th October 2006)

• Record Type: Journal Article
• Authors: Palmieri, C; MacGregor, T; Girgis, S; Vigushin, D
• Is Part Of: Journal of clinical pathology. Volume 59:Issue 12(2006)
• Page Start: 1334
• Page End: 1336
• Publication Date: 2006-10-17
• Subjects: 1, 25(OH)2D, 1, 25-dihydroxyvitamin D -- 25(OH)D, 25-hydroxyvitamin D -- PTH, parathyroid hormone; Pathology -- Periodicals; Pathology, Molecular -- Periodicals; 616.0705
• DOI: 10.1136/jcp.2006.042747
• Languages: English
• ISSNs: 0021-9746

Abstract

Abstract : Background: Laboratory and epidemiological studies have implicated vitamin D deficiency in the pathogenesis of breast cancer. 1, 25-Dihydroxyvitamin D (1, 25(OH)2 D) promotes differentiation and apoptosis, and potently inhibits proliferation of malignant breast epithelial cells in culture. Serum levels of 1, 25(OH)2 D are higher in normal women than in patients with primary breast cancer. Aim: To clarify the role of vitamin D in breast cancer progression by comparing the levels of serum vitamin D in patients with early and in those with advanced breast cancer. Methods: Circulating levels of 25-hydroxyvitamin D (25(OH)D), parathyroid hormone (PTH) and calcium were measured prospectively in 279 Caucasian women with invasive breast cancer, 204 women with early-stage disease and 75 women with locally advanced or metastatic disease. Results: Patients with early-stage breast cancer had significantly higher circulating levels of 25(OH)D (p<0.005) and significantly lower PTH (p<0.001) levels than those with advanced disease. Calcium levels did not differ significantly (p = 0.74). Conclusion: Serum levels of 25(OH)D are significantly higher in patients with early-stage breast cancer than in those with locally advanced or metastatic disease.